Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.

被引：3
|
作者：
Lemmon, Christopher
Zabor, Emily Craig
Pennell, Nathan A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8527
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
    Lemmon, Christopher A.
    Zabor, Emily C.
    Pennell, Nathan A.
    [J]. ONCOLOGIST, 2022, 27 (05): : 407 - 413
  • [2] Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
    Verhoek, Andre
    Cheema, Parneet
    Melosky, Barbara
    Samson, Benoit
    Shepherd, Frances A.
    de Marinis, Filippo
    John, Thomas
    Wu, Yi-Long
    Heeg, Bart
    Van Dalfsen, Nadia
    Bracke, Benjamin
    Miranda, Miguel
    Shaw, Simon
    Moldaver, Daniel
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (03) : 455 - 467
  • [3] Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
    Andre Verhoek
    Parneet Cheema
    Barbara Melosky
    Benoit Samson
    Frances A. Shepherd
    Filippo de Marinis
    Thomas John
    Yi-Long Wu
    Bart Heeg
    Nadia Van Dalfsen
    Benjamin Bracke
    Miguel Miranda
    Simon Shaw
    Daniel Moldaver
    [J]. PharmacoEconomics - Open, 2023, 7 : 455 - 467
  • [4] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ortega-Franco, Ana
    Rafee, Shereen
    [J]. ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22
  • [5] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ana Ortega-Franco
    Shereen Rafee
    [J]. Oncology and Therapy, 2022, 10 : 13 - 22
  • [6] A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN PATIENTS WITH RESECTED EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN PORTUGAL
    Andrade, A.
    Tavares, A. L.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S64 - S64
  • [7] CARDIOVASCULAR EVENTS IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER ON OSIMERTINIB
    Peleg, Ariel
    Ibtida, Ishmam
    Liu, Jennifer
    Steingart, Richard
    Yu, Anthony
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3288 - 3288
  • [8] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    [J]. PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [9] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [10] Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China
    Zhou, Xiwen
    Du, Jianting
    Xu, Guobing
    Chen, Chun
    Zheng, Bin
    Chen, Jiahe
    [J]. CANCER MEDICINE, 2022, 11 (23): : 4449 - 4456
12345